OBJECTIVE: To examine the change in total symptoms, and symptom clusters, of depression in newly abstinent opioid-dependent individuals being treated withdepot naltrexone (Depotrex; Biotek, Inc., Wellesley, MA). METHOD: In a series of opioid-dependent patients (N = 34) treated with naltrexone maintenance and relapse prevention therapy, mood was assessed with a 17-item Hamilton Depression (HAM-D) Scale and subscale scores at baseline, and after naltrexone induction at 2- and 4-week post-baseline. Data were analyzed using generalized estimated equation (GEE) models. RESULTS: Patients demonstrated high baseline affective burden and significant improvement of depression scores over a 4-week period post-baseline (F(2.66) = 8.88; p = .0004). Somatic and cognitive-affective subscale scores significantly declined as well as the seven individual item scores. By contrast, the "late insomnia" item score significantly increased at 2 weeks post-baseline. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Naltrexone induction and maintenance in newly abstinent opioid-dependent individuals does not appear to be associated with worsening of depression; however, it may be associated with sleep impairment early in treatment.
RCT Entities:
OBJECTIVE: To examine the change in total symptoms, and symptom clusters, of depression in newly abstinent opioid-dependent individuals being treated with depot naltrexone (Depotrex; Biotek, Inc., Wellesley, MA). METHOD: In a series of opioid-dependent patients (N = 34) treated with naltrexone maintenance and relapse prevention therapy, mood was assessed with a 17-item Hamilton Depression (HAM-D) Scale and subscale scores at baseline, and after naltrexone induction at 2- and 4-week post-baseline. Data were analyzed using generalized estimated equation (GEE) models. RESULTS:Patients demonstrated high baseline affective burden and significant improvement of depression scores over a 4-week period post-baseline (F(2.66) = 8.88; p = .0004). Somatic and cognitive-affective subscale scores significantly declined as well as the seven individual item scores. By contrast, the "late insomnia" item score significantly increased at 2 weeks post-baseline. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Naltrexone induction and maintenance in newly abstinent opioid-dependent individuals does not appear to be associated with worsening of depression; however, it may be associated with sleep impairment early in treatment.
Authors: Kenneth M Carpenter; Huiping Jiang; Maria A Sullivan; Adam Bisaga; Sandra D Comer; Wilfrid Noel Raby; Adam C Brooks; Edward V Nunes Journal: Psychol Addict Behav Date: 2009-03
Authors: Jami L Rothenberg; Maria A Sullivan; Sarah H Church; Angela Seracini; Eric Collins; Herbert D Kleber; Edward V Nunes Journal: J Subst Abuse Treat Date: 2002-12
Authors: Abdulrahman Almatroudi; Stephen M Husbands; Christopher P Bailey; Sarah J Bailey Journal: J Psychopharmacol Date: 2015-06-04 Impact factor: 4.153
Authors: Arthur Robin Williams; Vincent Barbieri; Kaitlyn Mishlen; Frances R Levin; Edward V Nunes; John J Mariani; Adam Bisaga Journal: Am J Addict Date: 2017-03-22
Authors: Edward V Nunes; Adam Bisaga; Evgeny Krupitsky; Narinder Nangia; Bernard L Silverman; Sarah C Akerman; Maria A Sullivan Journal: Addiction Date: 2019-08-04 Impact factor: 6.526
Authors: Kathleen M Carroll; Charla Nich; Tami L Frankforter; Sarah W Yip; Brian D Kiluk; Elise E DeVito; Mehmet Sofuoglu Journal: Drug Alcohol Depend Date: 2018-10-04 Impact factor: 4.492
Authors: Adam Bisaga; Paolo Mannelli; Maria A Sullivan; Suzanne K Vosburg; Peggy Compton; George E Woody; Thomas R Kosten Journal: Am J Addict Date: 2018-04
Authors: Eline R Zaaijer; Lonneke van Dijk; Kora de Bruin; Anna E Goudriaan; Laureen A Lammers; Maarten W J Koeter; Wim van den Brink; Jan Booij Journal: Psychopharmacology (Berl) Date: 2015-03-12 Impact factor: 4.530